Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 8/20 | 0.54 |
| ▸ | CA1 | P00915 | 4/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | XBP1 | P17861 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17471992 | 0.77 | CA2 (0.58) | CA2CA1MAPK1ATMGAA | |
| SCHEMBL17617151 | 0.75 | CA2 (0.70) | CA2CA1MAPK1ATMGAA | |
| SCHEMBL154056 | 0.75 | CA2 (0.70) | CA2CA1MAPK1ATMGAA | |
| SCHEMBL17617127 | 0.75 | CA2 (0.70) | CA2CA1MAPK1ATMGAA | |
| SCHEMBL332831 | 0.75 | CA2 (0.70) | CA2CA1MAPK1ATMGAA | |
| SCHEMBL2405187 | 0.75 | CA2 (0.70) | CA2CA1MAPK1ATMGAA | |
| SCHEMBL17938476 | 0.74 | CA2 (0.54) | CA2CA1MAPK1ATMGAA | |
| SCHEMBL1477902 | 0.73 | CA2 (0.68) | CA2CA1MAPK1ATMGAA | |
| SCHEMBL1421638 | 0.73 | CA2 (0.68) | CA2CA1MAPK1ATMGAA | |
| SCHEMBL333259 | 0.73 | CA2 (0.68) | CA2CA1MAPK1ATMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124829-A1 | Brominated esters, methods for their preparation and use thereof as flame retardants | BROMINE COMPOUNDS LTD. (IL) | 2005-06-09 | — | — | US | disclosed |
| EP-1478615-A1 | BROMINATED ESTERS, METHODS FOR THEIR PREPARATION AND USE THEREOF AS FLAME RETARDANTS | Bromine Compounds Ltd. (IL) | 2004-11-24 | — | — | EP | disclosed |
| WO-2003070685-A1 | BROMINATED ESTERS, METHODS FOR THEIR PREPARATION AND USE THEREOF AS FLAME RETARDANTS | BROMINE COMPOUNDS LTD. (IL) | 2003-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124829-A1 | Brominated esters, methods for their preparation and use thereof as flame retardants | CYP2F1, POLL, EBP | CA2 2437/4885CA1 2217/4885MAPK1 3639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.